S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1

Åström, Lennart; Weimarck, Anna; Aldenborg, Frank; Delle, Ulla; Hanson, Charles; Verbienė, Ingrida; Danielsson, Anna; Hammarsten, Jan; Köpf, I

doi:10.1002/(sici)1097-0215(19981218)79:6<553::aid-ijc1>3.0.co;2-s

Cited by 9 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional clinical and laboratory studies may add to the precision of predicting the natural history of the disease or response to therapy. DNA ploidy and S-phase fraction have been studied on radical prostatectomy specimens and appear to be valuable markers for progression and recurrence of disease [5,8,9,18]. Immunostaining for p53 has been suggested to be an independent predictor of disease progression after radical prostatectomy [4], but reports in the litterature are conflicting [7].…”

Section: Introductionmentioning

confidence: 99%

Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma

Alaiya

Roblick

Egevad

et al. 2000

Analytical Cellular Pathology

View full text Add to dashboard Cite

Cells were collected from prostate hyperplasias (n=6) and prostate carcinomas (n=6) and subjected to two‐dimensional gel electrophoresis (2‐DE). The resulting polypeptide patterns were analysed with the PDQUEST computer software. Malignant tumors showed significant increases in the level of expression of proliferating cell nuclear antigen (PCNA), calreticulin, HSP 90 and pHSP 60, oncoprotein 18(v), elongation factor 2, glutathione‐S‐transferase π (GST‐π), superoxide dismutase and triose phosphate isomerase. In addition, decreases in the levels of tropomyosin‐1 and 2 and cytokeratin 18 were observed in prostate carcinomas compared to prostate hyperplasias. This pattern of alterations is similar to that observed in other carcinomas in our previous studies. All malignant tumors showed simultaneous alterations in 5 or more of 9 markers studied, whereas only one case of benign hyperplasia showed alterations in 5 markers. The EST‐data base for prostate tumors available from NCI (CGAP) was searched for the expression of the mRNAs corresponding to proteins identified in our gels. Large differences in the relative expression of mRNAs and proteins were observed. Our data show alterations in the pattern of polypeptide expression in prostate carcinomas which are similar to those observed in other carcinomas.

show abstract

Section: Introductionmentioning

confidence: 99%

Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma

Alaiya

Roblick

Egevad

et al. 2000

Analytical Cellular Pathology

View full text Add to dashboard Cite

show abstract

Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer

Ren

Liu

Mao

et al. 2012

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

We recently found that TMPRSS2:ERG fusion genes and PTEN loss, which are common in Western prostate cancers are infrequent in Chinese cases. As previous studies indicated a higher frequency of RAS and BRAF mutation rates in Eastern Asian than in Western prostate cancers and fusion genes involving the RAF family genes BRAF and RAF1 were recently identified in prostate cancer in the American population, we investigated BRAF and RAF1 alterations in Chinese prostate cancer. Using fluorescence in situ hybridization, we found that BRAF was truncated in five of 200 informative Chinese cases (2.5%) and that RAF1 was truncated in three of 204 informative cases (1.5%) and genomic rearrangements of these genes were significantly correlated with high Gleason scores (>7; P < 0.01) and have a trend to appear in high clinical stage disease. A high frequency of BRAF and RAF1 copy number gain was found (29 and 15%, respectively). BRAF copy number gain in Chinese cancers was significantly higher than in UK cases (9.2%)(P < 0.001) and correlated with a number of clinical parameters. High-level expression of BRAF was found by immunohistochemistry in Chinese cancer samples compared with adjacent nonmalignant epithelial cells, which was correlated with high BRAF copy number. We also identified KRAS codon 12 mutations in three of 96 Chinese cases, no BRAF V600E mutations were observed. Our finding suggests that the activation of the RAS/RAF/MEK/ERK pathway may be frequent in Chinese prostate cancer, with RAF gene copy number gain potentially being the main contributor.

show abstract